Showing results (41-50 of 52) with videos related to

Sort By:
Pageof 6
Neuro-Oncology Advances|June 16, 2021
MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastomaPratik Talati, Mohamed El-Abtah, Daniel Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 19, 2018
Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 AntagonismVarun V Prabhu, Neel S Madhukar, Coryandar Gilvary, et al.
Neuro-Oncology|December 15, 2025
Prognostic Significance of MGMT Promoter Methylation Status in IDH-mutant GliomaGilbert Youssef, Elisa Aquilanti, Julie J Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 9, 2024
ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline GliomaIsabel Arrillaga-Romany, Sharon L Gardner, Yazmin Odia, et al.
Cancer Cell|April 5, 2024
Mutant IDH inhibitors induce lineage differentiation in IDH-mutant oligodendrogliomaAvishay Spitzer, Simon Gritsch, Masashi Nomura, et al.
Neuro-Oncology Advances|February 6, 2025
Ivosidenib for the treatment of IDH1-mutant glioma, grades 2-4: Tolerability, predictors of response, and outcomesTyler A Lanman, Gilbert Youssef, Raymond Huang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 22, 2026
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control DataTulika Rudra Gupta, Mei-Yin C Polley, Robert Redd, et al.
Pageof 6